Atara Biotherapeutics Inc

Atara Biotherapeutics Inc

ATRA

Get informed when a big investor buys or sells

+ Follow
Market Cap$90.73M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Atara Biotherapeutics IncAtara Biotherapeutics Inc-15.3-25%11.2-0.3
$13.00

Target Price by Analysts

16.5% upsideAtara Biotherapeutics Target Price DetailsTarget Price
$-2.33

Current Fair Value

120.9% downside

Overvalued by 120.9% based on the discounted cash flow analysis.

Share Statistics

Market cap$90.73 Million
Enterprise Value$92.13 Million
Dividend Yield$- (-)
Earnings per Share$2.61
Beta0.11
Outstanding Shares14,081,000

Return

Return on Equity25.37%ROE
Return on Assets-47.34%
Return on Invested Capital-50.80%

Valuation & Multiples

P/E Ratio-15.26P/E Ratio
PEG13.76PEG
Price to Sales11.16Price to Sales
Price to Book Ratio-3.72Price to Book Ratio
Enterprise Value to Revenue4.68
Enterprise Value to EBIT-12.64
Enterprise Value to Net Income-10
Total Debt to Enterprise0.11
Debt to Equity-0.26Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
May 21, 2026
EPS Estimate
$-0.33
Average shareholder expectation
Revenue Estimate
$2.90 M
Average shareholder expectation

Next Earnings Call

Expected Date
August 10, 2026
EPS Estimate
$-0.32
Average shareholder expectation
Revenue Estimate
$550,000
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls2000%
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %20.44%▲ 5.33%
Total Invested$12.13M▼ 67.28%
Investors Holding34▼ 8.00%

ESG Score

No data

About Atara Biotherapeutics Inc

CEO: Pascal Touchon